Investigational Drug Information for Marizomib
What is the drug development status for Marizomib?
Marizomib is an investigational drug.
There have been 12 clinical trials for Marizomib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 26th 2018.
The most common disease conditions in clinical trials are Glioma, Neoplasms, Plasma Cell, and Glioblastoma. The leading clinical trial sponsors are Celgene, Triphase Research and Development I Corporation, and Triphase.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Marizomib
| US Patents | 1,363 |
| International Patents | 5,435 |
| US Patent Applications | 3,779 |
| WIPO Patent Applications | 1,425 |
| Japanese Patent Applications | 273 |
| Clinical Trial Progress | Phase 2 (2018-07-26) |
| Vendors | 40 |
Recent Clinical Trials for Marizomib
| Title | Sponsor | Phase |
|---|---|---|
| Marizomib Central Nervous System (CNS) | Bristol-Myers Squibb | Phase 2 |
| Marizomib Central Nervous System (CNS) | Dana-Farber Cancer Institute | Phase 2 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG | Celgene | Phase 1 |
Clinical Trial Summary for Marizomib
Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib
US Patents for Marizomib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Marizomib | ⤷ Start Trial | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Start Trial |
| Marizomib | ⤷ Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Start Trial |
| Marizomib | ⤷ Start Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Start Trial |
| Marizomib | ⤷ Start Trial | Small molecule HSP70 inhibitors | The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Marizomib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Marizomib | Australia | AU2011279250 | 2030-07-12 | ⤷ Start Trial |
| Marizomib | Australia | AU2012249401 | 2030-07-12 | ⤷ Start Trial |
| Marizomib | Australia | AU2012249419 | 2030-07-12 | ⤷ Start Trial |
| Marizomib | Australia | AU2012249493 | 2030-07-12 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
Marizomib Development Update and Market Projection
Marizomib is a discontinued or inactive investigational proteasome inhibitor with no FDA approval, no commercial sales and no active registrational program publicly identified after a negative Phase 3 glioblastoma study. The EORTC 1709-CE “STRATE” trial failed to improve overall survival when marizomib was added to radiotherapy and temozolomide in newly diagnosed glioblastoma. The base-case commercial forecast is therefore zero revenue through 2030, with only a low-probability rescue scenario in a narrower brain-tumor or combination setting.
What is the current development status of marizomib?
Marizomib, also known as salinosporamide A or NPI-0052, is an irreversible epoxyketone proteasome inhibitor originally developed by Nereus Pharmaceuticals. Its development rationale was based on potent inhibition of the 20S proteasome and penetration into the central nervous system, a limitation associated with some earlier proteasome inhibitors.
Celgene acquired Nereus in 2008. Bristol Myers Squibb acquired Celgene in 2019 and inherited marizomib. The drug was developed primarily for glioblastoma, with earlier studies also evaluating multiple myeloma and other hematologic malignancies.
The decisive program was the international Phase 3 EORTC 1709-CE trial, known as STRATE. The study evaluated marizomib in combination with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
| Development item | Status |
|---|---|
| Active ingredient | Marizomib, salinosporamide A |
| Mechanism | Irreversible 20S proteasome inhibition |
| Primary sponsor lineage | Nereus Pharmaceuticals, Celgene, then Bristol Myers Squibb |
| Lead indication | Newly diagnosed glioblastoma |
| Phase 3 study | EORTC 1709-CE STRATE |
| Regulatory status | Not approved |
| FDA application | No public NDA approval |
| Commercial availability | None |
| Current development outlook | Low probability of resumption |
The Phase 3 results did not support regulatory submission. The trial showed no overall-survival advantage and raised tolerability concerns, particularly neurologic and systemic adverse events. Publicly available development activity has not indicated a new Phase 3 program or a replacement sponsor.
What did the Phase 3 glioblastoma trial show?
The STRATE study compared standard radiotherapy and temozolomide with the same regimen plus marizomib. The addition of marizomib did not improve the primary efficacy outcome.
| Measure | Standard therapy | Marizomib combination | Interpretation |
|---|---|---|---|
| Median overall survival | Approximately 22.2 months | Approximately 17.3 months | Numerically worse with marizomib |
| Overall-survival hazard ratio | Reference | Approximately 1.09 | No benefit |
| Progression-free survival | Approximately 6.5 months | Approximately 6.2 months | No meaningful improvement |
| Safety | Established toxicity profile | More treatment-related toxicity | Negative risk-benefit balance |
The results were reported in The Lancet Oncology. The study did not demonstrate that marizomib improved survival when added to the current glioblastoma backbone of surgery, radiotherapy and temozolomide.[1]
The failure is commercially significant because the Phase 3 program tested the most valuable initial indication: newly diagnosed glioblastoma, where patient volume is higher than in recurrent disease and treatment adoption can occur across oncology centers. A negative result in this setting materially reduces the value of the remaining development options.
Is marizomib FDA approved, and what is its Orange Book status?
Marizomib is not FDA approved and does not have an FDA Orange Book listing. It has no approved indication, no established commercial dosage form and no FDA-recognized market exclusivity period.
| FDA and exclusivity item | Marizomib status |
|---|---|
| FDA approval | None |
| NDA or BLA | No approved application publicly identified |
| Orange Book listing | None |
| New chemical entity exclusivity | Not granted |
| Orphan-drug exclusivity | No commercial exclusivity period granted |
| Pediatric exclusivity | None |
| Generic competition | No approved generic product |
| Biosimilar competition | Not applicable |
Marizomib is a small molecule rather than a biologic. A future generic would therefore be regulated through an abbreviated new drug application rather than a biosimilar pathway. That distinction has no immediate commercial effect because there is no reference product or approved label.
What patents protect marizomib?
The marizomib intellectual-property position is expected to include compound, synthesis, formulation and method-of-use patent families originating with Nereus and later controlled through Celgene and Bristol Myers Squibb. The principal commercial value of any original compound patent has declined because marizomib entered clinical development more than 15 years ago and failed its lead Phase 3 program.
The relevant protection categories are:
| Patent category | Commercial relevance |
|---|---|
| Compound patents | Protect marizomib and related salinosporamide structures |
| Manufacturing patents | Address fermentation, isolation, purification and stereochemical control |
| Formulation patents | Could cover injectable compositions, stability or dosing systems |
| Method-of-use patents | Could cover glioblastoma, recurrent brain tumors or combinations |
| Combination patents | Could cover marizomib with temozolomide, radiotherapy or other oncology agents |
No Orange Book-listed patent protects marizomib because there is no approved product. Patent expiration cannot be used to create a conventional generic-entry timetable in the same way as for an approved drug. Any future development would depend on the surviving term, scope and enforceability of individual patent families, including terminal disclaimers, patent-term adjustment and jurisdiction-specific expiration rules.
The practical IP position is weak for a new standalone commercial launch. A future sponsor would likely need to rely on a later method-of-use, formulation or manufacturing patent rather than on a broad, unexpired compound claim. Those narrower rights would not necessarily prevent development of alternative proteasome inhibitors or competing treatment regimens.
What formulations and delivery systems were developed?
Marizomib was developed primarily as an intravenous treatment. Its clinical use required repeated infusion and combination with standard glioblastoma therapy.
The development profile did not establish a commercially differentiated oral, implantable or depot formulation. That limits its competitive position against oral proteasome inhibitors in multiple myeloma and makes administration more burdensome in glioblastoma, where patients already receive radiotherapy, temozolomide and supportive care.
Potential formulation and manufacturing barriers include:
- Maintaining chemical and stereochemical stability of an irreversible epoxyketone compound.
- Controlling production of a marine-derived natural product or semisynthetic intermediate.
- Establishing reproducible impurity and degradation profiles.
- Supporting sterile intravenous manufacturing.
- Managing central nervous system exposure without increasing neurologic toxicity.
The manufacturing platform could create technical barriers to entry, but those barriers do not compensate for the lack of clinical efficacy. Manufacturing complexity is commercially protective only when the product has a validated therapeutic advantage or an approved market.
Which companies are challenging marizomib?
No company is publicly challenging marizomib through a Paragraph IV filing, generic launch, biosimilar application or active patent litigation. The reason is straightforward: marizomib has no approved reference product and no commercial market to attack.
| Competitive activity | Current status |
|---|---|
| Paragraph IV litigation | None publicly identified |
| ANDA filing | None publicly identified |
| Biosimilar filing | Not applicable |
| Patent settlement | None publicly identified |
| Generic launch | None |
| Active commercial sponsor | No active program publicly established |
The main competitive threat was clinical rather than legal. Standard glioblastoma therapy, investigational immunotherapies, tumor-treating fields and other targeted approaches competed for the same treatment setting. In proteasome inhibition, bortezomib, carfilzomib and ixazomib had stronger commercial positions because of established multiple-myeloma approvals, although those products did not establish a direct commercial substitute in glioblastoma.
What is the patent litigation and settlement status?
No material marizomib patent litigation or Paragraph IV settlement has been publicly reported. There is no Orange Book patent dispute because the drug has never obtained FDA approval.
The absence of litigation does not indicate strong exclusivity. It reflects the absence of a marketed product, an approved label and an economically attractive generic target. If a sponsor revived marizomib, litigation risk would more likely arise from method-of-use and formulation patents than from an existing Orange Book dispute.
When does marizomib lose exclusivity?
Marizomib has no active FDA-granted market exclusivity because it has never been approved. The practical loss of exclusivity occurred through clinical failure rather than a single patent expiration date.
A future approval could theoretically create new regulatory exclusivity for a new indication, but the drug would need to return to clinical development and generate positive evidence. Any such exclusivity would depend on the approval pathway, indication, orphan designation and patent rights available at the time.
The most likely exclusivity scenarios are:
| Scenario | Exclusivity implication |
|---|---|
| No development restart | No commercial exclusivity and no sales |
| New study in glioblastoma | Possible new method-of-use protection, subject to patentability |
| Orphan indication | Potential seven-year U.S. orphan exclusivity if approved |
| New formulation | Potential formulation patent, with limited scope |
| Combination approval | Potential method or combination patent protection |
| Generic development | No current reference-product pathway |
How strong is the marizomib patent estate?
The patent estate has moderate historical breadth but low current commercial strength.
Its historical strengths were the novelty of the salinosporamide structure, the distinct epoxyketone mechanism and the possibility of using marizomib in a central-nervous-system cancer setting. Its current weaknesses are the age of the underlying development program, the absence of an approved product, the negative Phase 3 result and the lack of a clear follow-on indication.
| Patent-strength factor | Assessment |
|---|---|
| Original compound novelty | Historically strong |
| Remaining broad compound protection | Likely limited by filing age |
| FDA Orange Book leverage | None |
| Method-of-use value | Low after negative glioblastoma Phase 3 data |
| Formulation value | Potentially relevant but narrow |
| Manufacturing protection | Technically meaningful, commercially unproven |
| Litigation leverage | Low without an approved market |
| Overall commercial patent strength | Low |
What is the market opportunity for marizomib?
The addressable market was concentrated in glioblastoma, a rare and highly aggressive brain cancer. The United States records roughly 13,000 to 15,000 new glioblastoma cases annually, although estimates vary by classification system and reporting year.[2] Only a portion of patients would be eligible for a marizomib combination because of age, performance status, surgical status, organ function and treatment tolerance.
A successful product could have generated revenue from:
- Newly diagnosed glioblastoma.
- Recurrent glioblastoma.
- High-grade glioma and related central nervous system tumors.
- Selected hematologic malignancies, particularly multiple myeloma.
- Combination use with temozolomide, radiotherapy or other anticancer agents.
The lead market was not large by oncology standards. A hypothetical commercial opportunity would have depended on a high specialty-oncology price, broad adoption across neuro-oncology centers and evidence of improved survival. The STRATE result removed the principal basis for those assumptions.
What is the projected revenue for marizomib?
The base-case revenue projection is zero through 2030 because there is no approved product, no launch plan and no active registrational evidence.
| Forecast scenario | Probability view | 2030 annual revenue | Peak-sales potential |
|---|---|---|---|
| Base case: program remains inactive | Highest | $0 | $0 |
| Rescue in a narrow recurrent-brain-tumor setting | Low | Below $10 million | Below $25 million |
| New positive CNS indication with major sponsor | Very low | $25 million to $100 million | $100 million to $250 million |
| Broad glioblastoma approval | Remote after Phase 3 failure | $100 million-plus | Unlikely |
These figures are scenario estimates, not reported company guidance. A relaunch would require a new sponsor, a credible biological rationale, a redesigned clinical program and a clear explanation for the negative STRATE outcome. The market would likely discount the asset heavily until a new efficacy signal appeared.
A renewed program in multiple myeloma would face entrenched competition from approved proteasome inhibitors and established treatment combinations. A renewed glioblastoma program would face a smaller patient pool, high clinical-trial failure rates and the need to overcome prior negative randomized evidence.
What generic launch risks exist?
There is no near-term generic launch risk because marizomib has no approved reference product. If marizomib were approved in the future, generic risk would initially be limited by the need to establish a reference product, obtain approval and address any surviving patents or regulatory exclusivity.
The larger risk is development abandonment. Investors and licensees face a high probability that the asset produces no commercial product, regardless of residual patent life. A future generic challenge would be a secondary issue after regulatory reactivation.
How does marizomib compare with competing proteasome inhibitors?
| Drug | Primary commercial status | Administration | Main market | Relevance to marizomib |
|---|---|---|---|---|
| Bortezomib | FDA approved | Injectable, with subcutaneous use | Multiple myeloma and mantle-cell lymphoma | Established proteasome-inhibitor benchmark |
| Carfilzomib | FDA approved | Intravenous | Multiple myeloma | Competes in hematology |
| Ixazomib | FDA approved | Oral | Multiple myeloma | More convenient chronic dosing |
| Marizomib | Investigational, no approval | Intravenous | Failed glioblastoma program | No commercial foothold |
Marizomib’s differentiation was its intended central nervous system penetration and irreversible proteasome inhibition. Its disadvantages were intravenous administration, toxicity concerns and failure to improve survival in the pivotal glioblastoma setting.
What is the investment and licensing outlook?
Marizomib has limited licensing value as a standalone asset. A transaction would be more plausible for a distressed-asset portfolio, an academic consortium or a company with a proprietary glioblastoma combination platform than for a large pharmaceutical company seeking a near-term revenue product.
Potential transaction structures would likely include:
- Low upfront consideration.
- Milestone-heavy economics.
- Rights limited to a geographic region or indication.
- Reversion provisions if a new study fails.
- Access to historical clinical and manufacturing data.
- Combination-focused development rather than monotherapy.
Bristol Myers Squibb’s inherited ownership gives the program a clear corporate lineage, but ownership does not establish current development intent. The negative Phase 3 outcome and lack of an approved indication reduce the value of any remaining asset package.
Key Takeaways
- Marizomib is an investigational irreversible proteasome inhibitor with no FDA approval.
- The Phase 3 EORTC STRATE trial failed to improve survival in newly diagnosed glioblastoma.
- Marizomib had worse numerical overall-survival results than standard therapy in the reported trial.
- There is no Orange Book listing, Paragraph IV challenge, generic launch or biosimilar pathway.
- The underlying patent estate has limited current commercial leverage because the program is old and unapproved.
- The base-case revenue forecast through 2030 is $0.
- A rescue program would require a new sponsor, a new indication or combination strategy and new clinical evidence.
- Multiple myeloma is commercially unattractive as a fallback because approved proteasome inhibitors already dominate that market.
- Manufacturing complexity may limit competition but does not resolve the drug’s clinical and regulatory failure.
FAQs
Could marizomib still be approved for glioblastoma?
Approval is possible only through a new clinical program producing positive efficacy data. The failed Phase 3 trial makes a direct resubmission or label expansion highly unlikely.
Does marizomib have orphan-drug exclusivity?
No commercial orphan-drug exclusivity has been granted because marizomib has not been approved. A future orphan designation would not itself create market exclusivity without approval.
Is marizomib a biosimilar risk?
No. Marizomib is a small molecule. Any future competitor would pursue a generic drug pathway rather than a biosimilar pathway.
What was the key reason for marizomib’s commercial failure?
The primary reason was failure of the Phase 3 glioblastoma trial to improve overall survival, combined with an unfavorable tolerability profile and the absence of a validated backup indication.
Could marizomib be repurposed for multiple myeloma?
A repurposing strategy is scientifically possible, but commercial prospects are weak because bortezomib, carfilzomib and ixazomib already have approved indications, mature clinical evidence and established market access.
References
-
Wick, W., Gorlia, T., Bendszus, M., et al. (2023). Marizomib plus temozolomide and radiotherapy versus temozolomide and radiotherapy in newly diagnosed glioblastoma: The EORTC 1709-CE trial. The Lancet Oncology.
-
Ostrom, Q. T., Cioffi, G., Wa sub, M., et al. (2023). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro-Oncology, 25(Supplement 4).
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene. Company release.
-
Nereus Pharmaceuticals. (2008). Celgene and Nereus enter agreement for acquisition of Nereus Pharmaceuticals. Company release.
More… ↓
